COSM Cosmos Health Inc.
Price Chart
Executive Summary
Cosmos Health announced strong sales momentum for its proprietary antiseptic brands C-Scrub and C-Sept, with over $1.5 million in combined annualized sales and gross margins above 70%. The company outlined a three-year growth target to reach $7.4 million in revenue by 2028, but this press release is a business update, not an earnings release—no financial results for Q1 2026 were provided. The filing lacks current-period revenue, EPS, or guidance figures, making it a forward-looking narrative with no hard data to validate.
Actionable Insight
This is a forward-looking business update with no hard financials—traders should wait for the actual Q1 2026 earnings release (if any) to assess performance. The three-year targets are aspirational and not guidance; monitor for concrete sales data in future filings.
Key Facts
- C-Scrub and C-Sept have generated over $1.5 million in combined annualized sales across the UK and Greece.
- Gross margins on these brands exceed 70%.
- Three-year revenue target: ~$2.5M (2026), ~$4.2M (2027), ~$7.4M (2028), with corresponding gross profit targets.
- Expansion into additional EU markets and animal healthcare is planned.
- No current-period financial results (Q1 2026) were reported in this press release.
Financial Impact
The press release outlines aspirational revenue targets of $2.5M-$7.4M over three years, but no current financial data is provided. The $1.5M annualized sales figure is modest relative to the company's market cap of $13M.
Risk Factors
- No current financial results were provided; the press release is purely narrative.
- Three-year targets are aspirational and may not be achieved; no assurance of reaching stated revenue or margin goals.
- The company has a history of negative EPS and small market cap ($13M), increasing execution risk.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311086 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 17, 2026
3d ago
|
Press Release
| $0.2417 $0.2129 | ▼ −11.92% | ▼ −12.70% | $0.2130 (−11.87%) |
|
Jun 12, 2026
8d ago
|
Press Release
| $0.2100 $0.2371 | ▲ +12.90% | ▲ +11.14% | $0.2130 (+1.43%) |
|
Jun 12, 2026
8d ago
|
Press Release
| $0.2100 $0.2371 | ▲ +12.90% | ▲ +11.14% | $0.2130 (+1.43%) |
|
Jun 10, 2026
10d ago
|
Press Release
| $0.2281 $0.2060 | ▼ −9.69% | ▼ −11.39% | $0.2130 (−6.62%) |
|
Jun 9, 2026
11d ago
|
Press Release
| $0.2233 $0.2281 | ▲ +2.15% | ▲ +3.73% | $0.2130 (−4.61%) |
|
Jun 8, 2026
12d ago
|
Press Release
| $0.2300 $0.2233 | ▼ −2.91% | ▼ −2.62% | $0.2130 (−7.39%) |
|
Jun 6, 2026
15d ago
|
S-3/A
| $0.2300 $0.2233 | ▲ +2.91% | ▲ +2.62% | $0.2130 (+7.39%) |
|
Jun 5, 2026
15d ago
|
DEFA14A
| $0.2300 $0.2233 | ▼ −2.91% | ▼ −2.62% | $0.2130 (−7.39%) |
|
Jun 1, 2026
19d ago
|
Press Release
| $0.2530 $0.2610 | ▲ +3.16% | ▲ +3.02% | $0.2130 (−15.81%) |
|
May 26, 2026
25d ago
|
Press Release
| $0.2630 $0.2650 | ▲ +0.76% | ▲ +0.75% | $0.2130 (−19.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access